SCHEMBL6397135

SCHEMBL6397135

O=P(O)(O)c1cccc(O)c1C(O)(O)Cc1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 4/20 0.39
ESR1 P03372 3/20 0.36
ALPG P10696 1/20 0.35
PTK2B Q14289 1/20 0.35
ESR2 Q92731 2/20 0.33
BLM P54132 1/20 0.33
KEAP1 Q14145 1/20 0.33
GGPS1 O95749 2/20 0.33
ACHE P22303 1/20 0.33
SGMS1 Q86VZ5 1/20 0.33
SGMS2 Q8NHU3 1/20 0.33
CYP19A1 P11511 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396228 0.86 ACHE (0.37) FDPSESR1ALPGPTK2BESR2
SCHEMBL6394421 0.86 GGPS1 (0.40) FDPSALPGPTK2BGGPS1CYP1A2
SCHEMBL6401821 0.83 ACHE (0.41) FDPSESR1ESR2GGPS1ACHE
SCHEMBL6397933 0.82 FDPS (0.38) FDPSESR1ESR2BLMACHE
SCHEMBL6398517 0.80 INPPL1 (0.42) FDPSESR1ESR2BLMKEAP1
SCHEMBL6397129 0.79 ESR1 (0.33) FDPSESR1ESR2BLMKEAP1
SCHEMBL6397392 0.78 ESR1 (0.36) ESR1ESR2PTPN1
SCHEMBL6403755 0.75 ESR1 (0.34) ESR1ESR2CYP3A4PTPN1
SCHEMBL6396873 0.75 DRD2 (0.40)
SCHEMBL6396081 0.74 ESR1 (0.35) ESR1ESR2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 FDPS 813/4885ESR1 2885/4885ALPG 749/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 FDPS 837/4885ESR1 3212/4885ALPG 682/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 FDPS 813/4885ESR1 2885/4885ALPG 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.